Total Payments
$101,545
2022 Payments
$1,031
Companies
8
Transactions
88
Medicare Patients
103
Medicare Billing
$4,924
Payment Breakdown by Category
Consulting$33,080 (32.6%)
Research$33,051 (32.5%)
Other$21,409 (21.1%)
Travel$11,781 (11.6%)
Food & Beverage$2,216 (2.2%)
Education$8.12 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $33,080 | 10 | 32.6% |
| Unspecified | $33,051 | 9 | 32.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $17,909 | 11 | 17.6% |
| Travel and Lodging | $11,781 | 21 | 11.6% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $3,500 | 1 | 3.4% |
| Food and Beverage | $2,216 | 35 | 2.2% |
| Education | $8.12 | 1 | 0.0% |
Payments by Type
General
$68,494
79 transactions
Research
$33,051
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $40,028 | 25 | $0 (2018) |
| Jazz Pharmaceuticals Inc. | $25,944 | 27 | $0 (2017) |
| Celgene Corporation | $21,964 | 24 | $0 (2019) |
| PFIZER INC. | $6,408 | 3 | $0 (2017) |
| Astellas Pharma Global Development | $5,200 | 4 | $0 (2019) |
| F. Hoffmann-La Roche AG | $1,252 | 2 | $0 (2022) |
| Amgen Inc. | $550.00 | 1 | $0 (2017) |
| Pharmacyclics LLC, An AbbVie Company | $198.78 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $1,031 | 1 | F. Hoffmann-La Roche AG ($1,031) |
| 2019 | $6,086 | 5 | Astellas Pharma Global Development ($5,200) |
| 2018 | $12,252 | 17 | Celgene Corporation ($7,323) |
| 2017 | $82,176 | 65 | Novartis Pharmaceuticals Corporation ($35,321) |
All Payment Transactions
88 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/30/2022 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $1,030.72 | Research |
| Study: PHASE 1B, OPEN-LABEL STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY ADMINISTERED IN COMBINATION WITH HU5F9-G4 TO PATIENTS WITH RELAPSED ANDOR REFRACTORY ACUTE MYELOID LEUKEMIA • Category: BioOncology | ||||||
| 08/28/2019 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $2,000.00 | Research |
| Study: Economic Burden of Illness among Patients with AML in the US A Retrospective Database Analysis • Category: ONCOLOGY | ||||||
| 03/25/2019 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $2,000.00 | Research |
| Study: Economic Burden of Illness among Patients with AML in the US A Retrospective Database Analysis • Category: ONCOLOGY | ||||||
| 02/13/2019 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $500.00 | Research |
| Study: Economic Burden of Illness among Patients with AML in the US A Retrospective Database Analysis • Category: ONCOLOGY | ||||||
| 01/09/2019 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $700.00 | Research |
| Study: Economic Burden of Illness among Patients with AML in the US A Retrospective Database Analysis • Category: ONCOLOGY | ||||||
| 01/03/2019 | Celgene Corporation | Idhifa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $886.00 | General |
| Category: Hematology | ||||||
| 12/03/2018 | Celgene Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $967.00 | General |
| 12/02/2018 | Celgene Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,082.00 | General |
| 12/02/2018 | Celgene Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,082.00 | General |
| 10/01/2018 | Celgene Corporation | Idhifa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $2,866.00 | General |
| Category: Hematology | ||||||
| 09/30/2018 | F. Hoffmann-La Roche AG | Erivedge (Biological) | — | In-kind items and services | $221.43 | Research |
| Study: A PHASE IBII STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VISMODEGIB IN RELAPSEDREFRACTORY ACUTE MYELOGENOUS LEUKEMIA AML AND RELAPSEDREFRACTORY HIGH-RISK MYELODYSPLASTIC SYNDROME MDS • Category: BioOncology | ||||||
| 08/01/2018 | Celgene Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $442.00 | General |
| 08/01/2018 | Celgene Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $442.00 | General |
| 08/01/2018 | Celgene Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $442.00 | General |
| 05/03/2018 | Novartis Pharmaceuticals Corporation | RYDAPT (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: HEMATOLOGY | ||||||
| 04/12/2018 | Novartis Pharmaceuticals Corporation | RYDAPT (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: HEMATOLOGY | ||||||
| 04/04/2018 | Novartis Pharmaceuticals Corporation | RYDAPT (Drug) | Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: HEMATOLOGY | ||||||
| 04/04/2018 | Novartis Pharmaceuticals Corporation | RYDAPT (Drug) | Travel and Lodging | In-kind items and services | $205.18 | General |
| Category: HEMATOLOGY | ||||||
| 04/04/2018 | Novartis Pharmaceuticals Corporation | RYDAPT (Drug) | Travel and Lodging | Cash or cash equivalent | $157.76 | General |
| Category: HEMATOLOGY | ||||||
| 04/04/2018 | Novartis Pharmaceuticals Corporation | RYDAPT (Drug) | Travel and Lodging | Cash or cash equivalent | $72.00 | General |
| Category: HEMATOLOGY | ||||||
| 04/04/2018 | Novartis Pharmaceuticals Corporation | RYDAPT (Drug) | Food and Beverage | In-kind items and services | $50.33 | General |
| Category: HEMATOLOGY | ||||||
| 04/03/2018 | Novartis Pharmaceuticals Corporation | RYDAPT (Drug) | Travel and Lodging | In-kind items and services | $647.00 | General |
| Category: HEMATOLOGY | ||||||
| 03/20/2018 | Novartis Pharmaceuticals Corporation | RYDAPT (Drug) | Food and Beverage | In-kind items and services | $10.17 | General |
| Category: HEMATOLOGY | ||||||
| 12/28/2017 | Celgene Corporation | Revlimid (Drug) | Consulting Fee | Cash or cash equivalent | $3,250.00 | General |
| Category: Hematology / Oncology | ||||||
| 12/11/2017 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $140.29 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $21,557 | 1 |
| Economic Burden of Illness among Patients with AML in the US A Retrospective Database Analysis | Astellas Pharma Global Development | $5,200 | 4 |
| CC-5013-AML-001 | Celgene Corporation | $2,533 | 1 |
| AG-221-C-001 | Celgene Corporation | $2,509 | 1 |
| PHASE 1B, OPEN-LABEL STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY ADMINISTERED IN COMBINATION WITH HU5F9-G4 TO PATIENTS WITH RELAPSED ANDOR REFRACTORY ACUTE MYELOID LEUKEMIA | F. Hoffmann-La Roche AG | $1,031 | 1 |
| A PHASE IBII STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VISMODEGIB IN RELAPSEDREFRACTORY ACUTE MYELOGENOUS LEUKEMIA AML AND RELAPSEDREFRACTORY HIGH-RISK MYELODYSPLASTIC SYNDROME MDS | F. Hoffmann-La Roche AG | $221.43 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 15 | 28 | $11,254 | $737.32 |
| 2022 | 1 | 17 | 28 | $10,864 | $794.31 |
| 2021 | 1 | 23 | 49 | $19,012 | $1,323 |
| 2020 | 2 | 48 | 71 | $21,076 | $2,069 |
Total Patients
103
Total Services
176
Medicare Billing
$4,924
Procedure Codes
5
All Medicare Procedures & Services
5 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 15 | 28 | $11,254 | $737.32 | 6.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 17 | 28 | $10,864 | $794.31 | 7.3% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 23 | 49 | $19,012 | $1,323 | 7.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 24 | 36 | $9,489 | $1,250 | 13.2% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Facility | 2020 | 24 | 35 | $11,587 | $819.26 | 7.1% |
About Dr. Bruno Medeiros, MD
Dr. Bruno Medeiros, MD is a Hematology & Oncology healthcare provider based in Stanford, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1760420657.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bruno Medeiros, MD has received a total of $101,545 in payments from pharmaceutical and medical device companies, with $1,031 received in 2022. These payments were reported across 88 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($33,080).
As a Medicare-enrolled provider, Medeiros has provided services to 103 Medicare beneficiaries, totaling 176 services with total Medicare billing of $4,924. Data is available for 4 years (2020–2023), covering 5 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology
- Location Stanford, CA
- Active Since 06/03/2006
- Last Updated 04/15/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1760420657
Products in Payments
- RYDAPT (Drug) $36,702
- VYXEOS (Drug) $15,306
- BOSULIF (Drug) $6,408
- Idhifa (Drug) $6,315
- Revlimid (Drug) $5,843
- XOSPATA (Drug) $5,200
- Vidaza (Drug) $4,953
- TECENTRIQ (Biological) $1,031
- Blincyto (Biological) $550.00
- TASIGNA (Drug) $326.40
- Erivedge (Biological) $221.43
- Imbruvica (Drug) $198.78
- CC-486 (Drug) $148.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Stanford
Everett Meyer, Md Phd, MD PHD
Hematology & Oncology — Payments: $2.1M
Hematology & Oncology $2.1M
Sandra Horning, M.d, M.D
Hematology & Oncology — Payments: $1.9M
Hematology & Oncology $1.9M
George Fisher, Md, MD
Hematology & Oncology — Payments: $202,617
Hematology & Oncology $202,617
Joel Neal, M.d., Ph.d, M.D., PH.D
Hematology & Oncology — Payments: $169,917
Hematology & Oncology $169,917
Lipika Goyal, Md, MD
Hematology & Oncology — Payments: $157,376
Hematology & Oncology $157,376
David Miklos, M.d., Ph. D, M.D., PH. D
Hematology & Oncology — Payments: $131,666
Hematology & Oncology $131,666